Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XB371 in advanced or metastatic solid tumors
NCT07123103Phase 1Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Aug 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of XB371 in solid tumor, sponsored by Exelixis, Inc. Primary endpoints: Number of Participants with a Dose-limiting Toxicity at 21 days and Number of Participants with a Treatment-emergent Adverse Event at 7 months. Started Aug 2025; status: recruiting.
02
Drugs
XB371
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07123103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123103.